Table 2 Perioperative outcomes of 100 bladder cancer patients

Operative time, [min, mean ± SD (range)]

255.73 ± 47.71 (138–390)

253.00 ± 43.89 (171–381)

259.07 ± 52.31 (138–390)

Estimated blood loss (EBL), [mL, mean ± SD (range)]

101.70 ± 57.53 (20–300)

97.64 ± 59.44 (50–300)

106.67 ± 55.35 (20–250)

Transfusion rate, [n (%)]

10 (10.00)

5 (9.09)

5 (11.11)

Day to flatus, [d, mean ± SD (range)]

2.48 ± 1.64 (1–6)

2.25 ± 1.49 (1–6)

2.76 ± 1.77 (1–6)

Day to regular diet, [d, mean ± SD (range)]

7.47 ± 3.15 (4–20)

7.07 ± 2.99 (4–20)

7.96 ± 3.32 (5–19)

Day to pelvic drain removal, [d, mean ± SD (range)]

10.01 ± 3.52 (4–24)

9.58 ± 3.25 (5–21)

10.53 ± 3.80 (4–24)

Hospital stay after operation, [d, mean ± SD (range)]

11.72 ± 4.01 (5–26)

11.62 ± 3.72 (6–22)

11.84 ± 4.37 (5–26)

Pathology type, [n (%)]

 Transitional cell carcinoma

98 (98.00)

54 (98.18)

44 (97.78)

 Squamous cell carcinoma

2 (2.00)

1 (1.82)

1 (2.22)

 Lymph node yield, [n, mean ± SD]

18.13 ± 2.63

17.78 ± 3.03

18.56 ± 1.98

 Lymph node positive, [n (%)]

9 (9.00)

5 (9.09)

4 (8.89)

Pathologic T stage, [n (%)]

  ≤ T1

17 (17.00)

8 (14.55)

9 (20.00)

 T2

37 (37.00)

20 (36.36)

17 (37.78)

 T3

41 (41.00)

24 (43.64)

17 (37.78)

 T4

5 (5.00)

3 (5.45)

2 (4.44)

Pathologic N stage, [n (%)]

 N0

91 (91.00)

50 (90.91)

41 (91.11)

 N1

4 (4.00)

3 (5.45)

1 (2.22)

 N2

5 (5.00)

2 (3.64)

3 (6.67)

Mean treatment cost [$, mean (range)]^a

10,894.85 (6455.00–28,730.6)

10,087.56 (6455.00–26,921.35)

11,755.62 (7921.75–28,730.61)